These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34265280)

  • 21. Ginsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells.
    Liu ZH; Li J; Xia J; Jiang R; Zuo GW; Li XP; Chen Y; Xiong W; Chen DL
    Chem Biol Interact; 2015 Dec; 242():227-34. PubMed ID: 26482938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
    Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R
    Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors.
    Routholla G; Pulya S; Patel T; Abdul Amin S; Adhikari N; Biswas S; Jha T; Ghosh B
    Bioorg Chem; 2021 Sep; 114():105050. PubMed ID: 34120025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.
    Wang G; He J; Zhao J; Yun W; Xie C; Taub JW; Azmi A; Mohammad RM; Dong Y; Kong W; Guo Y; Ge Y
    PLoS One; 2012; 7(12):e52095. PubMed ID: 23251689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
    Yoo J; Kim SJ; Son D; Seo H; Baek SY; Maeng CY; Lee C; Kim IS; Jung YH; Lee SM; Park HJ
    Eur J Med Chem; 2016 Jun; 116():126-135. PubMed ID: 27060764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiproliferative and proapoptotic activities of 4-hydroxybenzoic acid-based inhibitors of histone deacetylases.
    Seidel C; Schnekenburger M; Dicato M; Diederich M
    Cancer Lett; 2014 Feb; 343(1):134-46. PubMed ID: 24080339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel harmine derivative, N-(4-(hydroxycarbamoyl)benzyl)-1-(4- methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxamide (HBC), as histone deacetylase inhibitor: in vitro antiproliferation, apoptosis induction, cell cycle arrest, and antimetastatic effects.
    Miao JF; Peng YF; Chen S; Gao WJ; Yang QX; Zhu P; Guo J; Tao J; Luo L; Zhang Y; Ling Y
    Eur J Pharmacol; 2018 Apr; 824():78-88. PubMed ID: 29428472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
    Liu J; Zhou J; He F; Gao L; Wen Y; Gao L; Wang P; Kang D; Hu L
    Eur J Med Chem; 2020 Apr; 192():112189. PubMed ID: 32151834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
    Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
    Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia.
    Ceccacci E; Minucci S
    Br J Cancer; 2016 Mar; 114(6):605-11. PubMed ID: 26908329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of HDACs inhibitors in childhood and adolescence acute leukemias.
    Masetti R; Serravalle S; Biagi C; Pession A
    J Biomed Biotechnol; 2011; 2011():148046. PubMed ID: 21318168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells.
    Valente S; Trisciuoglio D; Tardugno M; Benedetti R; Labella D; Secci D; Mercurio C; Boggio R; Tomassi S; Di Maro S; Novellino E; Altucci L; Del Bufalo D; Mai A; Cosconati S
    ChemMedChem; 2013 May; 8(5):800-11. PubMed ID: 23526814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity.
    Gaisina IN; Tueckmantel W; Ugolkov A; Shen S; Hoffen J; Dubrovskyi O; Mazar A; Schoon RA; Billadeau D; Kozikowski AP
    ChemMedChem; 2016 Jan; 11(1):81-92. PubMed ID: 26592932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
    Bali P; Pranpat M; Bradner J; Balasis M; Fiskus W; Guo F; Rocha K; Kumaraswamy S; Boyapalle S; Atadja P; Seto E; Bhalla K
    J Biol Chem; 2005 Jul; 280(29):26729-34. PubMed ID: 15937340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
    Feng T; Wang H; Su H; Lu H; Yu L; Zhang X; Sun H; You Q
    Bioorg Med Chem; 2013 Sep; 21(17):5339-54. PubMed ID: 23820574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status.
    Kim HM; Kim CS; Lee JH; Jang SJ; Hwang JJ; Ro S; Hyun YL; Choi J
    Breast Cancer Res Treat; 2011 Nov; 130(2):365-75. PubMed ID: 21184271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of histone deacetylase 10 (HDAC10) inhibitors that modulate autophagy in transformed cells.
    Zeyen P; Zeyn Y; Herp D; Mahmoudi F; Yesiloglu TZ; Erdmann F; Schmidt M; Robaa D; Romier C; Ridinger J; Herbst-Gervasoni CJ; Christianson DW; Oehme I; Jung M; Krämer OH; Sippl W
    Eur J Med Chem; 2022 Apr; 234():114272. PubMed ID: 35306288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a histone deacetylase 6 inhibitor and its biological effects.
    Lee JH; Mahendran A; Yao Y; Ngo L; Venta-Perez G; Choy ML; Kim N; Ham WS; Breslow R; Marks PA
    Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15704-9. PubMed ID: 24023063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
    Muthyala R; Shin WS; Xie J; Sham YY
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4320-4. PubMed ID: 26264503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.